25 followers 0 articles/week
Response to Yilmaz et al.

No abstract available

Thu Apr 4, 2024 03:12
HMOX1 regulates ferroptosis via mic14 and its impact on chemotherapy resistance in small-cell lung cancer

This study aimed to investigate the role and molecular mechanism of heme oxygenase-1 (HMOX1) in chemotherapy resistance in small-cell lung cancer (SCLC). Employed bioinformatics, qPCR, and Western Blot to assess HMOX1 levels in SCLC versus normal tissues and its prognostic relevance. CCK-8, flow cytometry, and thiobarbituric acid assays determined HMOX1’s...

Thu Apr 4, 2024 03:12
Anoikis-related lncRNA signature predicts prognosis and is associated with immune infiltration in hepatocellular carcinoma

Anoikis is a programmed cell death process triggered when cells are dislodged from the extracellular matrix. Numerous long noncoding RNAs (lncRNAs) have been identified as significant factors associated with anoikis resistance in various tumor types, including glioma, breast cancer, and bladder cancer. However, the relationship between lncRNAs and the...

Thu Apr 4, 2024 03:12
A phase 1 study of regorafenib and sildenafil in adults with advanced solid tumors

The purpose of this study is to establish the recommended phase 2 dose for regorafenib in combination with sildenafil for patients with advanced solid tumors. Secondary outcomes included identification of antitumor effects of regorafenib and sildenafil, toxicity of the combination, determination of PDE5 expression in tumor samples, and the impact of...

Thu Apr 4, 2024 03:12
Anlotinib plus Sintilimab achieved in an antitumor effect of complete remission in a patient with advanced hepatocellular carcinoma: a case report

Systemic therapies-based combination treatments have been developed rapidly in patients with advanced hepatocellular carcinoma (HCC). However, there are still a few patients not applicable to any recommended therapies, making it considerable to try new therapeutic options. Among them, anlotinib, a new oral tyrosine kinase inhibitor, is being widely...

Fri Mar 8, 2024 16:44

Build your own newsfeed

Ready to give it a go?
Start a 14-day trial, no credit card required.

Create account